6.46
+5.56%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About AlzeCure Pharma
Its shares trade on Nasdaq Stockholm under the ticker ALZCUR.ST. It has been listed since 28 November 2018. In the fiscal year to 31 December 2017, it reported revenue of SEK 883,385 and a net loss of SEK 10.8m. At that date it held total assets of SEK 56.0m and shareholders' equity of SEK 51.8m.
AlzeCure Pharma AB is a pharmaceutical research company. The company is headquartered in Huddinge, Stockholm. The company went IPO on 2018-11-28. The firm develops five drug candidates within its two main research programs, NeuroRestore and Alzstatin. The drug candidates in NeuroRestore stimulate a central signaling pathway in the brain that is essential for the functioning of nerve cells and has a strong genetic link to cognitive disorders, such as Alzheimer's disease. The main drug candidate, ACD855, is an already approved veterinary medicine available for the treatment of central nervous system (CNS) indications in animals and has undergone preclinical trials for human indications of impaired cognitive disorders. Alzstatin focuses on reducing the production of toxic amyloid beta (Aβ) protein in the brain. Aβ plays a central role in the pathology of Alzheimer’s disease and starts to accumulate in the brain many years before the first symptoms are recognized.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Nov 2018
- Employees
- 13
- Website
- alzecurepharma.se ↗
Leadership
Pay as last reported
- Mr. Thomas PollareChairman of the Board, since 2017SEK 179,000
- Mr. Martin JonssonChief Executive OfficerSEK 2.1m
- Ms. Birgitta LundvikChief Financial Officer
- Mr. Johan SandinChief Scientific Officer
- Mr. Pontus ForsellHead of Research and Discovery
- Ms. Marta SegerdahlHead of Development
- Ms. Janet HoogstraateDirector
- Mr. Jan LundbergDirector
- Ms. Eva LilienbergIndependent DirectorSEK 58,000
- Dr. Ragnar LinderIndependent DirectorSEK 90,000
- Mr. Mikael WidellHead of Communications and Investor Relations
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- AlzeCure Pharma AB develops five drug candidates in NeuroRestore and Alzstatin programs.
- ACD855 is an approved veterinary medicine for CNS indications in animals.
- NeuroRestore targets central signaling pathways linked to cognitive disorders like Alzheimer's.
Weaknesses
- The company employs only 13 full-time employees.
- AlzeCure Pharma AB has no commercialized products yet.
- The firm relies on preclinical trials for human indications of cognitive disorders.
Opportunities
- ACD855 has potential for human cognitive disorder treatments after preclinical trials.
- Alzstatin's focus on reducing amyloid beta protein in Alzheimer's disease offers market potential.
- NeuroRestore's genetic link to Alzheimer's could attract research partnerships.
Threats
- Alzheimer's disease pathology involves amyloid beta accumulation years before symptoms appear.
- The company faces competition in the pharmaceutical sector for Alzheimer's treatments.
- Preclinical trials for human indications may not lead to successful commercialization.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.